Supplemental Table 1: Characteristics of trials included in the individual participant data analysis, outcomes assessed and the analytic contrasts in which they were included

Country	Years of study	Study Name	Trial design	Author	Intervention Groups	Selection of biochemistry sub-sample	Endline samples				Outcomes assessed								Analysis Contrasts		
							supplementation														
								Hb	Ferritin	sTÍR	ZPP	Hepcidin	Zinc	Retinol	RBP	Folate	B12	All-trials analysis	Child-LNS only and	lysis Separation of multi- component arms	Passive control arms excluded
Bangladesh	2012-2014	JiVitA-4	cluster RCT; longitudinal	Christian, 2015 (35); Campbell,	Plumpy/Doz ¹ + IYCF counseling	Subset selected to be geographically continguous,	Y	Y	Y				Y	Ŷ				LNS	LNS	LNS	LNS
			tonow-up	2020 (15)	Chicknea based INS + IVCE counseling	accessible, socioeconomically representative and balanced by number of participants per treatment arm												LNS	LNS	LNS	LNS
																		LNS	LNS	LNS	LNS
					Wheat-soy blend (++) + IYCF counseling													control	control	control	control
Bangladesh	2011-2015	RDNS	cluster RCT: longitudinal	Dewey, 2017 (36); Matias, 2018 (1	IYCF counseling only (Control) 0	During enrollment, a total of 1346 (unborn) children	Ŷ	Y	Y	Y					Y			LNS			
			follow-up	,	⁴⁴ LNS-LNS: maternal SQ-LNS in pregnancy + 6 mo postpartum, child SC LNS 6-24 mo	were randomply assigned to the child blochemical sample															
					IFA-LNS: maternal IFA in pregnancy + 3 mo postpartum, child SQ-LNS 6-24 mo													LNS	LNS	LNS	LNS
					IFA-MNP: maternal IFA in pregnancy + 3 mo postpartum, child MNP 6-24 mo																
					IFA-Control: maternal IFA in pregnancy + 3 mo postpartum, no child supplementation													control	control	control	control
Bangladesh	2012-2015	WASH-Benefits	cluster RCT; cross-sectional surveys	Luby, 2018 (37); Stewart, 2019 (12	9 Nutrition: SQ-LNS + IYCF counseling	Sub-study clusters were selected based on the logistical I feasibility of the preservation and collection of	Dependent on age	Y	Y	Y		Y			Y	Y	Y	LNS	LNS	LNS	LNS
					Water: family received chlorine for drinking water	central laboratory												control	control		control
					Sanitation: family received upgraded latrine, sani-scoop and child notty	Exclusion criteria included symptoms of moderate to reverse debudration on the day of the runner												control	control		control
					Handwashing: family received handwashing stations with soap WASH: family received all water, sanitation and hygiene													control	control	control-WSH	control
					interventions WASH + nutrition: all water, sanitation, hygiene and nutrition													LNS	LNS	LNS-WSH	LNS
					Passive control (no intervention)													control	control	control	
Burkina Faso	2010-2012	ILINS-ZINC	cluster RCT; longitudinal	Hess, 2015 (38); Abbeddou 2017		Subset of 1065 children were randomly selected; one	Ŷ	Y	Ŷ	Y	γ		Y		Y			LNS	LNS	LNS	
			follow-up	(11)	LNS-2NU: SU-LNS containing u mg/d 2n and placebo tablet	child included per concession Excluded children with reported fever or diarrhea												INS	INS	INS	
					LNS-ZnS: SQ-LNS containing 5 mg/d Zn and placebo tablet	symptoms on the day of enrollment or on the scheduled blood collection day.												INS	INS	INS	
					LNS-Zn10: SQ-LNS containing 10 mg/d Zn and placebo tablet																
					LNS-TabZnS: SQ-LNS containing 0 mg/d Zn and Zn tablet containing 5 mg/d Zn													LNS	LNS	LNS	
					Passive control (no intervention)													control	control	control	
Burkina Faso	2015-2017	PROMIS	cluster RCT; cross-sectional surveys	Becquey, 2019 (39)	SQ-LNS + IYCF counseling	N/A (all children in cross-sectional survey > 3 months of 1 age)	Ŷ	Y										LNS	LNS	LNS	LNS
					Active control (standard of care)													control	control	control	control
Ghana	2004-2005		RCT; longitudinal follow-up	Adu-Afarwuah, 2007 (40); Adu- Afarwuah, 2008 (9)	SQ-LNS	N/A	Ŷ	Y	Y	Ŷ			Y	Y				LNS	LNS	LNS	
					MNP																
					Nutritabs (MMN)																
					Passive control (no intervention)													control	control	control	
Ghana	2009-2014	ILINS-DYAD-G	RCT; longitudinal follow-up	Adu-Afarwuah, 2016 (41); Adu- Afarwuah, 2019 (16)	LNS: maternal SQ-LNS in pregnancy + 6 mo postpartum, child SQ-LNS 6-18 mo	ZPP: measured in all; CRP/AGP: The subsample for the CRP and AGP analyses was selected from the children whose mothers were not prepared furing.	Y	Ŷ			Y			Ŷ		A ₃	Å ₃	LNS			
					MMN: maternal MMN in pregnancy + 6 mo postpartum, no child	the period when the temporary mislabeling occurred												control			
					supplementation IFA: maternal IFA in pregnancy and placebo for 6 mo postpartum, no													control			
Kenya	2012-2016	WASH-Benefits	cluster RCT; cross-sectional	Null, 2018 (42); Stewart, 2019 (12	child supplementation	Sub-study clusters were selected based on the logistical	Dependent on age	Y	Y	Y		Y			Y	Y	Ŷ	LNS	LNS	LNS	LNS
			surveys		Nutrition: SQ-UNS + IVCF counseling	feasibility of the preservation and collection of biological specimens, as well as their transport to the												control	control		control
					Water: family received chlorine for drinking water	central laboratory Exclusion criteria included sumetoms of moderate to												control	control		control
					potty	severe dehydration on the day of the survey.												control			
					Handwashing: family received handwashing stations with soap													control	control		control
					WASH: family received all water, sanitation and hygiene interventions													control	control	control-WSH	control
					WASH + nutrition: all water, sanitation, hygiene and nutrition interventions													LNS	LNS	LNS-WSH	LNS
					Passive control (no intervention)													control	control	control	
					Active control (visits to measure MUAC)													control	control	control	control
Madagascar	2014-2016	MAHAY	cluster RCT; longitudinal follow-up	Galasso, 2019 (43); Stewart, 2020 (13)	T4: early child stimulation + IYCF counseling	Subset of sites randomly samples among sites accessible via paved road; random sample of children from each site in the youngest age cohort (18-24 mo at	Dependent on age	Y	Y	Y					Ŷ			LNS			
					T3: maternal SQ-LNS in pregnancy + 6 mo postpartum, child SQ-LNS i 18 mo + IYCF counseling	; endline)															
					T2: child SQ-LNS 6-18 mo + IYCF counseling													LNS	LNS	LNS	LNS
					T1: IYCF counseling													control	control	control	control
					T0: Control (standard of care)													control	control	control	control
Malawi	2011-2014	ILINS-DYAD-M	RCT; longitudinal follow-up	Ashorn, 2015 (44)	LNS: maternal SQ-LNS in pregnancy + 6 mo postpartum, child SQ-LNS	N/A	Ŷ	Y			Ŷ			Ŷ		Y ²	Y ²	LNS			
					MMN: maternal MMN in pregnancy + 6 mo postpartum, no child sundementation													control			
					IFA: maternal IFA in pregnancy and placebo for 6 mo postpartum, no child supplementation													control			
Malawi	2009-2012	ILINS-DOSE	RCT; longitudinal follow-up	Maleta, 2015 (45) ⁴	SQ-LNS containing milk (10 g/d)	Random sub-sample of 100 children/group was selected	Ŷ	Y			Y							LNS	LNS	LNS	LNS
					SQ-LNS containing milk (20 g/d)													LNS	LNS	LNS	LNS
					SQ-LNS without milk (20 g/d)													LNS	LNS	LNS	LNS
					MD-LNS containing milk (40 g/d)																
					MD-INS without milk (40 g/d)																
					A strike service mark (so gray													control	control	control	control
Mali	2015-2017	PROMIS	cluster RCT; cross-sectional	Huybregts, 2019 (46)	Sector California	N/A (all children in cross-sectional survey)	Ŷ	Y										LNS	LINS	LNS	LNS
			surveys		SQ-LNS + IYCF counseling	· · · · · · · · · · · · · · · · · · ·															

					Active control (standard of care) + IYCF counseling									control	control	control	control
Zimbabwe	2013-2017	SHINE	cluster RCT; longitudinal follow-up	Humphrey, 2019 (47); Prendergast, 2019 (48) ⁵	* IYCF: child SQ-LNS + IYCF counseling	Sub-study included infants of women reaching 32 weeks' gestation visit from 1 May 2014 through the end	Dependent on age	Ŷ	A ₃	Y ^a	 A ₃	 	 	 LNS	LNS	LNS	LNS
					WASH : family received ventilated improved pit latrine, bandwarbing stations, come chloring, child pix rosco	of the trial; all HIV exposed infants included								control	control	control-WSH	control
					WASH and IYCF: child SQ-LNS + IYCF counseling, family received westlisted improved nit latrice, bandworkbing stations, room									LNS	LNS	LNS-WSH	LNS
					chlorine child nlav snare											an antical	
					Active control (standard of care)									control	CONDICI	control	CONTROL

FA, iron-folic acid; IFC; Infant and young child feeding; UKS; Ilpid-based nutrient supplement; WASH, water sanitation and hygiene; WSB, wheat ory blend; RC7; randomized controlled trial.

¹ All usadements were localoric children 6-12 no received 125 ka/ld, dildren 12-18 no received 250 kca/ld ² All clidlers in the float intervention groups received OR 56 for dambea and treatment for malara ¹ Data not yet analogue and the state of the ¹ Trial is clied as fammenda 200 in Das et al. (Exchance Database of Systematic Review 200) ¹ Trial was desimed as for informer et usis as analow for WW as mosed and une accound children: that considered as two comparisons in all analyses and the presentation of results

Supplemental Table 1. Amount of LNS provided (g/day) and nutrient value (per daily ration)

-			Revised iLiNS	Plumpy'Doz	Plumpy'Doz	Rice-lentil LNS	Rice-lentil LNS	Chickpea LNS	Chickpea LNS
	Nutributter ¹	iLiNS formulation ^{2,3}	formulation ⁴	(6-11 mo)⁵	(12-18 mo) ⁵	(6-11 mo)⁵	(12-18 mo) ⁵	(6-11 mo)⁵	(12-18 mo) ⁵
Ration (g/day)	20	20	20	23.2	46.4	25.7	51.4	23.6	47.2
Total energy (kcal)	108	118	118	123.4	246.8	133.9	267.8	128.6	257.2
Protein (g)	2.56	2.6	2.6	2.9	5.9	2.8	5.7	3.5	7.1
Fat (g)	7.08	9.6	9.6	7.9	15.8	6.9	13.9	6.6	13.2
Linoleic acid (g)	1.29	4.46	4.46						
α-Linolenic acid (g)	0.29	0.58	0.58						
Vitamin A (µg RE)	400	400	400	200	400	117.7	235.4	118.5	236.9
Vitamin C (mg)	30	30	30						
Vitamin B1 (mg)	0.3	0.3	0.5	0.3	0.5	0.3	0.6	0.3	0.6
Vitamin B2 (mg)	0.4	S	0.5	0.3	0.5	0.2	0.5	0.2	0.5
Niacin (mg)	4	4	6	2.8	5.6	2.6	5.1	2.4	4.7
Folic acid (µg)	80	80	150	80	160.1	100	199.9	118.2	236.5
Pantothenic acid (mg)	1.8	1.8	2	1	2	1.1	2.2	1	2
Vitamin B6 (mg)	0.3	0.3	0.5	0.3	0.5	0.3	0.6	0.3	0.6
Vitamin B12 (µg)	0.5	0.5	0.9	0.4	0.8	0.5	0.9	0.5	0.9
Vitamin D (IU) 1 IU = 0.025 ug	0	200	200			226.2	452.3	226.6	453.1
Vitamin E (mg)	0	6	6	3	6	4.9	9.8	4.7	9.4
Vitamin K (µg)	0	30	30			11.3	22.6	11.3	22.7
lron (mg)	9	6	9	4.5	9	3.3	6.7	3.5	7.1
Zinc (mg)	4	8	8	2	4	2.4	4.8	2.5	5.1
Copper (mg)	0.2	0.34	0.34	0.2	0.3	0.2	0.4	0.3	0.5
Calcium (mg)	100	280	280	193.5	387	208.2	416.3	219.5	439
Phosphorus (mg)	82	190	190	137.6	275.2	61.7	123.4	72.9	145.8
Potassium (mg)	152	200	200	155	310	206.6	413.3	220.7	441.3
Magnesium (mg)	16	40	40	29.9	59.9	41.6	83.3	47.7	95.3
Selenium (μg)	10	20	20	8.6	17.2	7.5	14.9	7.6	15.1
lodine (μg)	90	90	90	27.6	55.2	33.7	67.3	33.7	67.5
Manganese (mg)	0.08	1.2	1.2	0.1	0.1	0.5	0.9	0.4	0.9

¹Provided by Adu-Afarwuah 2007 (40)

²Provided by Hess 2015 (38), Becquey 2019 (39), Adu-Afarwuah 2016 (41), Galasso 2019 (43), Ashorn 2015 (44), Maleta 2015 (45), Huybregts 2019 (46), Humphrey 2019 (47), Prendergast 2019 (48).

³Hess 2015 (38) provided 0-10 mg zinc/d in the SQ-LNS product, plus a 5 mg/d zinc supplement in one intervention arm. Maleta 2015 (45) provided 10-40 g/d of LNS, with and without milk powder, varying by intervention arm (the 40 g arms were not included in this IPD analysis); the micronutrient composition of the LNS was identical across intervention arms, but there were differences in total kcal, protein, fat, linoleic acid and α-linolenic acid.

⁴Provided by Dewey 2017 (36), Luby 2018 (37), Null 2018 (42)

⁵Provided by Christian 2015 (35). Product and quantities differed by intervention arm and age.

Supplemental Table 3: Descriptive information on potential study-level effect modifiers, by trial

					Inflammation (CRP > 5	Inflammation AGP > 1	Water quality	Sanitation	Duration of			Average SQ-LNS		
Country	Author	Geographic Region	Malaria Prevalence (%)	Anemia Prevalence (%)	mg/L)	g/L)	(% improved)	(% improved)	supplementation	Iron dose (mg/d)	Frequency of contact	compliance (%)	Compliance definition (in the SQ-LNS group)	Source (Anemia previance)
														National Institute of Population Research and Training (NIPORT), Mitra and Associates, and ICF International. 2013.
Bangladesh	Christian, 2015 (35); Campbell, 2020 (15)	SEAR	0.2	51.3%	21% ⁵	59%°	100.0*	77.0*	< 12 mo	3.3-9 mg/d*	Weekly	93.0	% of total intended SQ-LNS consumed (quantity * day)	Bangladesh Demographic and Health Survey 2011. Dhaka, Bangladesh and Calverton, Maryland, USA: NIPORT, Mitra and
														National Institute of Population Research and Training (NIPORT), Mitra and Associates, and ICF International. 2013.
Bangladesh	Dewey, 2017 (36); Matias, 2018 (10)	SEAR	0.2	51.3%*	14%*	32%*	100.0*	71.1*	> 12 mo	9 mg/d	Monthly	97.4"	% reporting "high adherence (>4 days/week)	Bangladesh Demographic and Health Survey 2011. Dhaka, Bangladesh and Calverton, Maryland, USA: NIPORT, Mitra and
													Number of sachets consumed in 14 days prior to annual	National Institute of Population Research and Training (NIPORT), Mitra and Associates, and ICF International. 2013.
Bangladesh	Luby, 2018 (37); Stewart, 2019 (12)	SEAR	0.1"	51.3%"	11%	29%*	88.5	94.7	> 12 mo	9 mg/d	Weekly	93.0"	survey/14	Bangladesh Demographic and Health Survey 2011. Dhaka, Bangladesh and Calverton, Maryland, USA: NIPORT, Mitra and
Burbles Free	User 2015 (20) Abbedde: 2017 (21)	450	r0.1 ^b	ar av ^b	220/2	row ^b	25.2	2.20	. 12	6	Merchin	or #	K of days CO LNC second ad assessed	Institut Nacional de la statistique et de la Demographie (IVSD) et CP international, 2012, Englette Demographique et de
Burkina Paso	Hess, 2015 (58); Abbeddob 2017 (11)	Arn	55.1	67.6%	52%	3374	20.7	2.5	5 12 110	6 mg/u	weekiy	90.6	caregiver reported receiving SQ-LNS in the previour	Same et a morateus woropres de buncha raso zono, calveriori, maryano, osa : noso et icr internacional: Institut National de la Statisticiana at de la Démostrabilia (INSD) et ICC International, 2012, Sonvibte Démostrabiliana et de
Bushing Free	Becquer, 2019 (20)2	450	47 Q ^b	97 9% ^b			so s ^b	52 A ³	< 12 mo	C mald	Monthly	27.02	month	South at a logications Multiples du Burking Stron 2010, Chuestern Mandard USA : INSD at ICE International
Burkina Paso	becquey, 2023 (35)	arn	44.7	67.674			30.0	32.4	2 44 110	6 mg/u	montany	37.0	instan	Ghana et sintistical en la contra la contra la contra
Ghana	Adu-Afarwuah, 2007 (40); Adu-Afarwuah, 2008 (9)	AFR	37.4°	76.1% ^b	18%3		91.9	91.5 ^a	< 12 mo	9 mg/d	Weekly	88.2	% of days SO-LNS reported consumed	Demographic and Health Survey 2003. Calverton, Marvland: GSS. NMIMR, and ORC Macro.
														Ghana Statistical Service, 2011. Ghana Multiple Indicator Cluster Survey with an Enhanced Malaria Module and Biomarker,
Ghana	Adu-Afarwuah, 2016 (41); Adu-Afarwuah, 2019 (16)	AFR	36.8 ^b	57.0% ^a	18%	44%	98.4 ³	97.3 ^a	< 12 mo	6 mg/d	Weekly	73.5 ^b	% of days SO-LNS reported consumed	2011, Final Report, Accra, Ghana,
													Number of sachets consumed in 14 days prior to annual	National Malaria Control Programme (NMCP), Kenya National Bureau of Statistics (KNBS), and ICF International. 2016. Kenya
Kenya	Null, 2018 (42); Stewart, 2019 (12)	AFR	8.5	36.3%	21%3	47%	68.0 ^b	15.8 ^b	> 12 mo	9 mg/d	Monthly	115.0 ^a	survey/14	Malaria Indicator Survey 2015. Nairobi, Kenya, and Rockville, Maryland, USA: NMCP, KNBS, and ICF International.
														Institut National de la Statistique (INSTAT), Programme National de lutte contre le Paludisme (PNLP), institut Pasteur de
Madagascar	Galasso, 2019 (43); Stewart, 2020 (13)	AFR	5.5*	51.0% ^a	19%3	41%3	26.9 ^b	0.0 ^b	< 12 mo	6 mg/d	Monthly		Data unavailable.	Madagascar (IPM) et ICF International. 2013. Enquête sur les Indicateurs du Paludisme (EIPM) 2013. Calverton, MD, USA :
														National Statistical Office (NSO) and ICF Macro. 2011. Malawi Demographic and Health Survey 2010. Zomba, Malawi, and
Malawi	Ashorn, 2015 (44)	AFR	26.8 ⁹	62.5%	30%	68%°	91.7	9.2°	≤ 12 mo	6 mg/d	Weekly	77.1 ⁰	% of days SQ-LNS reported consumed	Calverton, Maryland, USA: NSO and ICF Macro.
													% of days SQ-LNS reported consumed (considering	National Statistical Office (NSO) and ICF Macro. 2011. Malawi Demographic and Health Survey 2010. Zomba, Malawi, and
Malawi	Maleta, 2015 (45)	AFR	30.3"	62.5%"	34%"	66%"	91.6"	2.9"	≤ 12 mo	6 mg/d	Weekly	71.6"	missed delivery visits)	Calverton, Maryland, USA: NSO and ICF Macro.
													caregiver reported receiving SQ-LNS in the previous	Institut National de la Statistique (INSIAI), Cellue de Planification et de Statistique Secteur Sante-Developpement Social
Mali	Huybregts, 2019 (46)*	AFR	39.1	81.8%			50.8"	75.3*	> 12 mo	6 mg/d	Monthly	47.0	month	et Promotion de la Famille (CPS/SS-DS-PF), et ICF. 2019. Sixième Enquête Démographique et de Santé au Mali 2018.
													received > 11 (80% of expected) deliveries * consumed	Zimbabwe National Statistics Agency and ICF International. 2016. Zimbabwe Demographic and Health Survey 2015: Final
Zimbabwe	Humphrey, 2019 (47); Prendergast 2019 (48) ²	AEB	9.0	36.8% ^a	21%		63.6 ^b	34.0 ^b	< 12 mo	6 mg/d	Monthly	73.5 ^b	SQ-LNS in past 24 h (at 12 month visit)	Report. Rockville, Maryland, USA: Zimbabwe National Statistics Agency (ZIMSTAT) and ICF International.

AFR, Africa Region; AGP, alpha-1-acid glycoprotein; CRP, C-reactive protein; SEAR, South-East Asia Region; SQ-LNS, small quantity lipid-based nutrient supplements

Tron dose varied by age and 50-145 intervention group (see Supplemental Table 2) "Study-level effect modifier categorization based on the longitudinal cohort, for constances with the growth and development domains of this individual participant data analysis "Study-level effect modifier categorizations was the amin for bath HT sepond and HTU une expond children Supportings as and beingingte the two categories, as described in Notes below.

Nets: Graphic region: based on WOP regions: Multi-lip previews: this extracted from Annex, Dist table 7: Population at risk and restinated malaris cases and deaths, 2000-2007 (wm/2018-mens-table f.sk); Print estimate (presumed and confirmed malaris cases), divided by population at risk, per 100 persons. Thisk were categorized as (a) low burden when malaris was: UBA and (b) high burden when annex as 2006. Multi-lip previews: The extracted from Annex, Dist table 7: Population at risk and restinated malaris cases and deaths, 2000-2007 (wm/2018-mens-table f.sk); Print estimate (presumed and confirmed malaris cases), divided by population at risk, per 100 persons. Thisk were categorized as (a) low burden when malaris was: UBA and (b) high burden when annex as 2006. Information was defeat as (D) Population at risk and restinated malaris cases and deaths, 2000-2007 (wm/2018-mens-table f.sk); Print estimate (presumed and confirmed malaris cases), divided by population at risk, per 100 persons. Thisk were categorized as (b) low burden when annex as 4006. Information was defeat categorized as (P) annex as 4006. Multi-lip previdence 2008 and (b) das Population at risk per deata set on settimated in the high of the print of

Santistion. Data based on sample privalences of improved santiation. Study-level santiation was considered as (a) improved if santiation servers for 29% of participants were improved; study-level santiation was considered as (b) unimproved if santiation servers for 49% of participants were improved; study-level santiation was considered as (b) unimproved if santiation servers for 49% of participants were improved; study-level santiation servers for 49% of participants were improved; study-level santiation servers for 49% of participants were improved; study-level santiation servers for 49% of participants were improved; study-level santiation servers for 49% of participants were improved; study-level santiation servers improved; study-level santiation servers; study-level santiation serve

Compliance: Data extracted from publication; study-specific definitions of compliance are noted in the table. Trials were categorized as (a) high compliance when compliance was 280% or (b) low compliance when compliance was < 80% compliance.

References

World Malaria Report 2018. Geneva: World Health Oreanization: 2018. Available at: https://www.who.int/malaria/publications/world-malaria-report-2018/report/en/

Supplemental Table 4: Descriptive information on potential individual-level effect modifiers, by trial

				Maternal							Baseline food				
				education,			Prevalence of	Prevalence of		Receipt of high-	security,			Improved	
		Maternal BMI <	Maternal age < 25	completed	Child sex, male	Child birth order,	baseline anemia	baseline acute	Inflammation at	dose vitamin A	moderate/severe	SES index, below	Improved source	sanitation access	Season at
Country	Author	20 kg/m ² (%)	y (%)	primary (%)	(%)	first born (%)	(%)	malnutrition (%)	endline (%)	(%)	insecurity (%)	median (%)	water quality (%)	(%)	endline, dry (%)
Bangladesh	Christian, 2015 (35); Campbell, 2020 (15)		54.2	65.2	50.8	75.4*		20.3	61.3	50.6	24.9 ^a	46.3	100.0	79.3	55.6
Bangladesh	Dewey, 2017 (36); Matias, 2018 (10)	58.2	71.7	73.1	48.5	37.8	60.8	6.0	34.5	81.2	38.2 ^b	50.2	100.0	69.3	61.8
Bangladesh	Luby, 2018 (37); Stewart, 2019 (12)	51.4	58.9	73.3	48.8	37.5			22.8	60.3	20.2 ^b	50.7	78.8	92.5	48.6
Burkina Faso	Hess, 2015 (38); Abbeddou 2017 (11)	38.8	41.3	3.7	50.6	22.1	90.9	25.7	61.4		48.9 ^b	41.4	26.7	2.3	71.5
Burkina Faso	Becquey, 2019 (39)	40.5	53.8	8.1	53.0	15.4						49.6	63.8	41.1	45.7
Ghana	Adu-Afarwuah, 2007 (40); Adu-Afarwuah, 2008 (9)	9.2	29.0	88.3	52.1	40.0			18.1	59.3		46.3	91.9	91.5	57.7
Ghana	Adu-Afarwuah, 2016 (41); Adu-Afarwuah, 2019 (16)	15.3	39.0	78.8	48.2	33.7	35.3	8.2	45.4	63.3	30.3 ^b	50.1	98.4	97.2	59.2
Kenya	Null, 2018 (42); Stewart, 2019 (12)	21.6	40.9	46.3	47.8	18.9			49.2	11.6	11.7 ^b	43.9	70.1	13.4	27.3
Madagascar	Galasso, 2019 (43); Stewart, 2020 (13)		47.0	22.8	47.6	23.0			43.3		28.4 ^b	49.0	26.4	0.0	88.7
Malawi	Ashorn, 2015 (44)	40.0	50.2	15.7	47.4	20.8	65.7	8.4	68.9	33.2	71.6 ^b	46.7	91.5	9.4	70.8
Malawi	Maleta, 2015 (45)	25.8	45.2	24.4	50.8	23.7	62.7	5.7	67.9		73.9 ^b	49.2	91.8	2.9	59.4
Mali	Huybregts, 2019 (46)	27.5	47.5	10.6	52.3	14.4						49.7	59.7	74.9	100.0
Zimbabwe	Humphrey, 2019 (HIV-unexposed) (47)	15.4	47.6	96.4	50.2	26.7		5.6	21.0	57.0	18.7 ^c	49.3	62.6	33.3	92.6
Zimbabwe	Prendergast, 2019 (HIV-exposed) (48)	18.1	22.9	94.3	49.9	19.7		8.4	15.5	54.3	25.1 ^c	49.3	61.8	30.6	93.7

Abbreviations: BMI. bodv mass index: SES. socio-economic status

Notes: Anemia: Hemoglobin < 110 g/L Baseline hemoglobin and anthropometric status (acute mainutrition) were measured at enrollment into the study or start of supplementation if supplementation did not begin at enrollment. These data are not available for studies with a repeated cross-sectional survey design, as the same individual children were not included in both baseline and endline surveys. Acute mainutrition: weight documents care to acutome assessment Wey/Anol Florid scurity scales used: a) food Access Survey Took (b) Household food Insecurity Access Sace (HATAS); c) Coping Strategy Index Water and samilation references - so for study-level fielder modifies. Secon is defined at time of outcome as setument as a dicitoronous sammer's as dicitoronous saturey, as it was conducted in the dry season (February-March). "Data on third were not available for all diluting the endline cross-sectional survey, as it was conducted in the dry season (February-March).

Supplemental Table 5: Description of biochemical assessments

Country	Author	Hen	noglobin (Hb)				Micronutrient status biomarke	rs			Innammation biomarkers				
		Hb sample	Hb method	MN sample	Ferritin	sTfR	ZPP	Zinc	Retinol	RBP	CRP	AGP	Malaria		
Bangladesh	Christian, 2015 (35); Campbell, 2020 (15)	Venous	Hemocue Hb 301	Venous, serum	Automated chemiluminescent immunoassay (Immulite 2000)			Graphite furnace AAS	Reverse-phase HPLC		Automated chemiluminescent asasy (Immulite 2000)	Radial immunodiffusion (Kent Laboratories)			
Bangladesh	Dewey, 2017 (36); Matias, 2018 (10)	Capillary	Hemocue Hb 301	Capillary, serum	Combined sandwich ELISA	Combined sandwich ELISA				Combined sandwich ELISA	Combined sandwich ELISA	Combined sandwich ELISA			
Bangladesh	Luby, 2018 (37); Stewart, 2019 (12)	Venous	Hemocue Hb 301	Venous, serum	Combined sandwich ELISA	Combined sandwich ELISA				Combined sandwich ELISA	Combined sandwich ELISA	Combined sandwich ELISA	Y		
Burkina Faso	Hess, 2015 (38); Abbeddou 2017 (11)	Capillary	Hemocue Hb 201+	Venous, plasma	Combined sandwich ELISA	Combined sandwich ELISA	Hematoflurometer (Aviv Biomedical); washed RBC	ICP-AES		Combined sandwich ELISA	Combined sandwich ELISA	Combined sandwich ELISA	RDT (Bioline Malaria Ag P.f/Pan)		
Burkina Faso	Becquey, 2019 (39)	Capillary	Hemocue Hb 201+												
Ghana	Adu-Afarwuah, 2007 (40); Adu-Afarwuah, 2008 (9)	Venous	Hemocue B- Hemoglobin	Venous, plasma	Coat-A-Count Immunoradiometric Assay Kit (Diagnostic Products)	ELISA (Ramco Laboratories)		ICP-AES	Reverse-phase HPLC		Radial immunodiffusion (Binding Site) Cobas Integra 400 plus Automatic	 Cobas Integra 400 plus Automatic	Blood smear (Giemsa stain)		
Ghana	Adu-Afarwuah, 2016 (41); Adu-Afarwuah, 2019 (16)	Venous	Hemocue Hb 301	Venous, plasma			Hematoflurometer (Aviv Biomedical); washed RBC		Reverse-phase HPLC		Analyzer (Roche); particle-enhanced turbidimetric assay	Analyzer (Roche); particle-enhanced turbidimetric assay	RDT (Clearview Malarial Combo, Vision Biotech; HRP2 and P.aldolase)		
Kenya	Null, 2018 (42); Stewart, 2019 (12)	Venous	Hemocue Hb 301	Venous, serum	Combined sandwich ELISA	Combined sandwich ELISA				Combined sandwich ELISA	Combined sandwich ELISA	Combined sandwich ELISA	RDT (Alere; SD Bioline Malaria Ag P.f/P.v)		
Madagascar	Galasso, 2019 (43); Stewart, 2020 (13)	Capillary	Hemocue Hb 301	Capillary, serum	Combined sandwich ELISA	Combined sandwich ELISA				Combined sandwich ELISA	Combined sandwich ELISA Cobas Integra 400 plus Automatic	Combined sandwich ELISA Cobas Integra 400 plus Automatic			
Malawi	Ashorn, 2015 (44)	Capillary	Hemocue Hb 201+	Venous, plasma			Hematoflurometer (Aviv Biomedical); washed RBC		Reverse-phase HPLC		Analyzer (Roche); particle-enhanced turbidimetric assay Cobas Integra 400 plus Automatic	Analyzer (Roche); particle-enhanced turbidimetric assay Cobas Integra 400 plus Automatic	RDT		
Malawi	Maleta, 2015 (45)	Capillary	Hemocue Hb 201+				Hematoflurometer (Aviv Biomedical); washed RBC				Analyzer (Roche); particle-enhanced turbidimetric assay	Analyzer (Roche); particle-enhanced turbidimetric assay	RDT		
Mali	Huybregts, 2019 (46)	Capillary	Hemocue Hb 201+												
Zimbabwe	Humphrey, 2019 (47): Prendergast 2019 (48)	Venous	Hemocue Hb 3011	Venous, plasma											

AS. atomic absorption sectroscopy. AGP. alpha-1-acid elycoproteins: RP. C-reactive eroteins: Hb. hemoalobin: RPC. hash eefformance liquid chromatoarashy: ICP-AES. inductively coupled alasma atomic emission sectroscopy. MM. micronutrient: RBC. red blood cells: RBP. retinol binding arotein: RDT. rasid alaenostic test: sTR. soluble transferrin recestor; ZPP. ainc protoaorathyrin

²Hemoglobin data were altitude adjusted (27)

Supplemental Table 6: Biomarker outcomes at endline among control groups, by trial

Country	Author																		
			Anemia, Hb < 11	0 Moderate to severe		Iron deficiency,	Iron deficiency				ZPP > 70				Retinol < 0.70	Retinol < 1.05			
		Hemoglobin, g/L	g/L	anemia, Hb < 100 g/L	Ferritin, µg/L	ferritin < 12 µg/L	anemia	sTfR, mg/L	sTfR > 8.3 mg/L	ZPP, µmol/mol heme	µmol/mol heme	Plasma zinc, µg/dL	Zinc < 65 µg/dL	Retinol, µmol/L	μmol	μmol	RBP, µmol	RBP < 0.70 µmol	RBP < 1.05 µmol
Bangladesh	Christian, 2015 (35); Campbell, 2020 (15)	118±9	15.8	1.4	23.4 (13.2, 37.2)	22.2	9.0					88.3 (80.2, 99.8)	2.1	1.35 (1.10, 1.70)	2.9	19.4			
Bangladesh	Dewey, 2017 (36); Matias, 2018 (10)	112 ± 14	41.9	16.5	21.1 (12.8, 32.0)	22.1	14.7	8.3 (7.0, 11.3)	50.0								1.19 (1.01, 1.44)	3.3	29.0
Bangladesh	Luby, 2018 (37); Stewart, 2019 (12)	118 ± 9	16.1	3.2	15.9 (8.9, 25.6)	35.4	10.1	7.5 (6.2, 8.6)	31.5								1.14 (0.96, 1.35)	1.1	35.4
Burkina Faso	Hess, 2015 (38); Abbeddou 2017 (11)	89 ± 16	91.1	75.0	9.7 (6.2, 18.6)	58.5	54.5	9.9 (6.6, 12.6)	61.3	122.2 (70.7, 181.1)	75.2	68.7 (62.7, 77.4)	36.2				1.06 (0.89, 1.20)	8.5	49.1
Burkina Faso	Becquey, 2019 (39)	103 ± 13	70.1	36.7															
Ghana	Adu-Afarwuah, 2007 (40); Adu-Afarwuah, 2008 (9)	106 ± 15	58.3	32.3	9.3 (3.2, 29.1)	56.1	35.4	9.6 (7.4, 12.8)	62.2			60.0 (53.9, 68.4)	68.1	1.08 (0.80, 1.33)	16.2	48.6			
Ghana	Adu-Afarwuah, 2016 (41); Adu-Afarwuah, 2019 (16)	112 ± 11	44.9	5.4						48.1 (33.8, 68.5)	24.3			1.01 (0.87, 1.20)	5.6	56.6			
Kenya	Null, 2018 (42); Stewart, 2019 (12)	110 ± 13	47.3	21.3	10.1 (6.3, 16.7)	59.1	33.3	10.9 (8.2, 15.5)	73.0								0.97 (0.80, 1.16)	9.3	59.5
Madagascar	Galasso, 2019 (43); Stewart, 2020 (13)	104 ± 16	64.8	32.8	11.6 (9.3, 18.5)	51.0	27.5	9.0 (7.2, 13.5)	58.8								1.09 (0.95, 1.28)	2.0	39.2
Malawi	Ashorn, 2015 (44)	108 ± 15	51.9	23.6						53.6 (36.1, 85.1)	33.6			1.05 (0.87, 1.20)	9.2	48.5			
Malawi	Maleta, 2015 (45)	101 ± 14	72.0	46.3						66.4 (40.1, 110.4)	44.8								
Mali	Huybregts, 2019 (46)	96 ± 13	86.2	60.2															
Zimbabwe	Humphrey, 2019 (HIV-unexposed) (47)	114 ± 12	35.3	10.6	NA			NA											
Zimbabwe	Prendergast, 2019 (HIV-exposed) (48)	115 ± 13	36.8	10.2	NA			NA											

Hb. hemoelobin: NA. data not vet available: RBP. retinol bindine ontein: STR. soluble transferrin recentor: ZPP. zinc orotooorohvrin Values are mean + 50. median (10. 103) or orevalences: All continuous biomarkers with the exceetion of hemoelobin, were natural los transformed orior to analysis Permin, STR. ZPR, inc. retinoi and RBP concentrations were adjuated for inflammation (a. C-reactive protein (CRP) and/or ox-1-acid phycorotein (AGP) concentrations, as available), using a regression correction approach adapted from the Biomarkers Reflecting Inflammation and Nutritional Determinants of Anemia (BRINDA) project (28)